Vertex Pharmaceuticals (NQ:VRTX)

Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off harder to call.

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? ↗

November 13, 2026

S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Session ↗

November 11, 2026

Via Chartmill

Topics Stocks

Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 Earnings: In-Line Revenue, Modest EPS Miss, Raised Guidance and Higher Spending ↗

November 02, 2026

Via Chartmill

BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? ↗

November 11, 2026

Vertex Pharmaceuticals earns steady profits from its cystic fibrosis medicines while expanding into new diseases. BioNTech has a large cash cushion and a growing cancer pipeline, but its COVID vaccine...

AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology

The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom ↗

November 11, 2026

Via MarketBeat

Topics Artificial Intelligence Bankruptcy

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation ↗

November 08, 2026

These are among the best the industry has to offer.

Bristol Myers trades at under 10 times forward earnings, while Vertex commands nearly triple that multiple, but its margins are roughly double.

Topics Intellectual Property

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? ↗

November 07, 2026

Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years ↗

November 05, 2026

The drugmaker hasn't disappointed long-term shareholders.

Topics Intellectual Property

Vertex to Participate in Upcoming Investor Conferences

November 04, 2026

Vertex is betting on nephrology and rare endocrinology to build a fifth and fourth commercial pillar beyond cystic fibrosis.

Vertex: 3 Key Takeaways for Long-Term Investors ↗

November 03, 2026

Revenue grew 12% as newer products like CASGEVY and JOURNAVX ramped up significantly.

Topics Earnings

Vertex (VRTX) Q3 2026 Earnings Call Transcript ↗

November 03, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 11.8% year on year t...

Topics Earnings

VRTX Q3 deep dive: Pipeline, product launches, and Crinetics integration shape outlook

November 03, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products...

Vertex Pharmaceuticals Q3 Earnings Call Highlights ↗

November 02, 2026

Via MarketBeat

Topics Earnings

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction ↗

November 02, 2026

Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 11.8% year on year...

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q3 2026 sales top estimates

November 02, 2026

Vertex Reports Third Quarter 2026 Financial Results

November 02, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...

Vertex Pharmaceuticals earnings: what to look for from VRTX

October 31, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Topics Artificial Intelligence

3 large-cap stocks with solid fundamentals

October 30, 2026

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue ↗

After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗

October 29, 2026

Via Chartmill

Topics Stocks

October 27, 2026

Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.

I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move ↗

Topics Intellectual Property Lawsuit

October 26, 2026

Here's how I'm staying calm as valuations hit record highs.

The company's gene-editing-focused platform looks promising.

Topics Artificial Intelligence Economy

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More ↗

October 24, 2026

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. ↗

October 24, 2026

Vertex is expanding beyond its cystic fibrosis franchise.

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy...

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III ↗

October 23, 2026

Via MarketBeat

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

October 23, 2026

S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines ↗

October 21, 2026

Via Chartmill

Topics Artificial Intelligence Stocks Supply Chain

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 20, 2026

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

Topics Intellectual Property

Vertex Appoints Daniel Brennan to its Board of Directors

October 20, 2026

Buffett has warned about "gambling" in the market.

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗

October 19, 2026